Bing

SEARCH HISTORY

Should I get rid of Mylan Labs, or hold on? A-You should love this stock. Hold and consider buying more shares of Mylan Laboratories Inc. (around $24 a share, New York Stock Exchange), because it is the class act in the generic drug industry, said Jerry ...
Chicago Tribune · 9/26/1994
Israeli pharmaceutical giant Teva offered to buy Mylan in a cash-and-stock deal valued at about $40.1 billion. The potential combination would result in a powerhouse of a generic drug developer competing against rivals such as Sun Pharma. According to ...
The Times of Israel · 4/21/2015
Mylan NV (MYL) made public on Wednesday that it had made a proposal to acquire Perrigo Co. plc (PRGO) in a deal valued at $205 per share in cash and stock, or close to $29 billion. Under the terms of the proposal, which was delivered to Perrigo's …
The Deal Pipeline · 4/8/2015
Shareholders too were evidently disappointed: Perrigo stock fell 4.3 percent. Teva meanwhile reiterated its $40.1 billion offer for Mylan. Mylan’s stock finished up 3.2 percent, and Teva, 1.8 percent. Comcast shares added 0.7 percent after they confirmed ...
Gulf News · 4/25/2015
Perrigo shares on the New York Stock Exchange initially jumped well above the Mylan offer price to as high as US$215.72, but slipped back to US$197.95. Mylan shares jumped more than 15 per cent to US$68.72 on Nasdaq.
Financial Post · 4/8/2015
Teva has offered to buy Mylan for about $40.1 billion in cash and stock in a deal that would create a powerhouse of generic drug development. Mylan, which reincoporated in the Netherlands, ships products from a center in Greensboro, N.C. PITTSBURGH — …
San Francisco Gate · 7/14/2015
Walt Disney Parks and Resorts and Disney Cruise Lines has inked a deal with Mylan Inc., the distributor of the EpiPen, to make stock epinephrine auto-injectors available at (or aboard) its key U.S. properties, including California’s Disneyland and ...
Allergic Living · 11/12/2014
Shares of Mylan traded below the offer price of $82 in cash and stock, evidence of investor scepticism that Teva can win over the company, which has set up a defence that includes a poison pill. Analysts agreed that Teva would need to sweeten its bid to ...
NDTV · 4/22/2015
This content is available to IFRe.com subscribers. Please login if you have a subscription. Alternatively, you can request a trial, or contact your IFR account manager for more information. If you have a subscription to IFRe, please enter your login details.
International Financing Review · 4/4/2015

Mylan

Company
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters …
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, Hertfordshire in the United Kingdom. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan now has approximately 30,000 employees, more than 1,000 separate products, and serves customers in more than 150 countries and territories. Mylan has a global manufacturing output of more than 45 billion doses.
Data from: Wikipedia · Freebase